Sekisui Chemical Company has acquired Genzyme Corporation’s Diagnostic Product Division
Lincoln International, a leading global mid-market investment bank, has announced that Sekisui Chemical Company, the Tokyo stock exchange-listed manufacturer of a broad range of products in Japan and internationally, has completed its acquisition of Genzyme Corporation’s Diagnostic Products division for $265 million in cash.
Genzyme Diagnostics is a leading provider of global diagnostic products for diagnostics manufacturers, clinical laboratories and physician offices. Sekisui acquired facilities in the U.S., Canada, Germany and the U.K. and is retaining approximately 575 employees.
Lincoln International acted as the exclusive financial advisor to Sekisui, working closely with the senior management team throughout the sale process. This included providing advisory expertise and managing the negotiation and due diligence phases of the transaction.
Meet our Senior Team
View More Transactions
Lincoln is pleased to have advised UK-based Woodall Nicholson on its sale to UK-based private equity investor Rutland Partners
Lincoln International is pleased to announce that it advised founding shareholders in the sale of Acture Groep
Lincoln International has advised Profile Search & Selection in its sale to Wilson HCG, a portfolio company of CIP Capital
Lincoln International is pleased to announce that Sandbox Group has been sold to MERGE, a portfolio company of Keystone Capital